SYBX vs. BNTC, SLGL, RNXT, MEIP, TCRT, CPIX, GDTC, BFRG, TXMD, and NNVC
Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Benitec Biopharma (BNTC), Sol-Gel Technologies (SLGL), RenovoRx (RNXT), MEI Pharma (MEIP), Alaunos Therapeutics (TCRT), Cumberland Pharmaceuticals (CPIX), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), TherapeuticsMD (TXMD), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical preparations" industry.
Synlogic (NASDAQ:SYBX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Benitec Biopharma has lower revenue, but higher earnings than Synlogic. Benitec Biopharma is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.
63.4% of Synlogic shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 8.0% of Synlogic shares are held by insiders. Comparatively, 4.3% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Synlogic presently has a consensus price target of $65.00, suggesting a potential upside of 3,375.94%. Benitec Biopharma has a consensus price target of $16.00, suggesting a potential upside of 85.19%. Given Synlogic's higher probable upside, analysts plainly believe Synlogic is more favorable than Benitec Biopharma.
In the previous week, Benitec Biopharma's average media sentiment score of 0.71 beat Synlogic's score of 0.67 indicating that Benitec Biopharma is being referred to more favorably in the news media.
Benitec Biopharma has a net margin of 0.00% compared to Synlogic's net margin of -1,699.23%. Synlogic's return on equity of -109.34% beat Benitec Biopharma's return on equity.
Synlogic received 150 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 63.73% of users gave Benitec Biopharma an outperform vote.
Synlogic has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Summary
Synlogic beats Benitec Biopharma on 10 of the 16 factors compared between the two stocks.
Get Synlogic News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synlogic Competitors List
Related Companies and Tools
